At least this is what NCI has to say about the lung cancer progrnostic biomarkers based on gene expression data. The markers themselves do exist, they are just not useful for the clinic, write Jyothi Subramanian, Ph.D., and Richard Simon of the biometric research branch at the NCI. The common problems include poor statistical validation of markers and lack of medical utility.
Advertisement
